Ramp­ing back up on on­col­o­gy, GSK takes an op­tion on Adap­ti­m­mune’s TCR can­cer drug

New GSK CEO Em­ma Walm­s­ley is go­ing for it in on­col­o­gy.

Look­ing to steer the phar­ma gi­ant back to­ward a pipeline that can stir some re­al ex­cite­ment among in­vestors, the GSK chief has de­cid­ed to pick up an ex­clu­sive op­tion on Adap­ti­m­mune’s NY-ESO SPEAR T-cell ther­a­py pro­gram.

Adap­ti­m­mune $ADAP is in line now for $61 mil­lion dur­ing the tran­si­tion pe­ri­od — part for the op­tion and part in mile­stones. GSK gets full rights cov­er­ing the de­vel­op­ment and hoped for com­mer­cial­iza­tion of the TCR ther­a­peu­tic, a tech cousin to the CAR-Ts now mak­ing their de­but.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER